Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|November 16, 2003
Controversies in common optic neuropathies
Typical optic neuritis, which presents with unilateral painful loss ofvision, is the most common optic neuropathy in young predominantly femalepatients. What is being recognized increasingly is that optic neuritis maybe the first indication of multiple sclerosis (MS). David Kaufmann, DO,of East Lansing, MI, noted that magnetic resonance imaging is the most importantdiagnostic tool and ophthalmologists are on the frontline of diagnosis ofMS. Research indicates that the 10-year risk of developing MS in all patientsis 38%; the risk in the presence of a normal MRI is 22%; in patients withone or more baseline lesions, the risk of MS is 56%.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Eyedaptic launches Eva, an agentic AI visual assistant for patients with retinal disease
2
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
3
Eyes on October 2026: AAO and EURETINA highlights, a trio of FDA approvals, and optogenetics takes the spotlight
4
Complement inhibition in GA: Timing, safety, and follow-up
5